APDA News

New Study Indicates that New Cases of Parkinson’s Disease are 50% Higher than Past Estimates

Posted on by Phil Franchina

The results of a new study show that the incidence of Parkinson’s disease (PD), or the number of new...see more cases diagnosed per year, is 50% higher than previously estimated. Instead of past estimates of 60,000 new cases of PD diagnosed per year, the new study determined that there are approximately 90,000 new cases of PD […]

Read More

Congress Introduces the National Plan to End Parkinson’s Act

Posted on by Phil Franchina

On Thursday, July 28, the U.S. House of Representatives introduced a bill entitled the NationalPlan to End Parkinson’s Act...see more and on Thursday September 15, a companion bill was introduced in the Senate. This was an exciting moment for the Parkinson’s disease (PD) community, as this Act acknowledged the need for our government to increase its […]

Read More

APDA-Funded Research Discovers New Role of Alpha Synuclein

Posted on by Phil Franchina

In an exciting new study, researchers at Brigham and Women’s Hospital in Boston, MA, led by APDA Cotzias Fellowship*...see more awardee Dr. Vikram Khurana, demonstrated a new role for the protein involved in Parkinson’s disease (PD) pathology, alpha-synuclein. In addition to alpha-synuclein interacting with vesicles, or small transport structures within the cell, this new study shows […]

Read More

New Treatment for Slowness & Stiffness in Parkinson’s Disease

Posted on by Dr. Rebecca Gilbert

In 2018, Focused Ultrasound was approved to treat tremors in people with PD.  Now, the FDA has approved expanding...see more the indications of Focused Ultrasound (FUS) for Parkinson’s disease (PD) to also include treatment of bradykinesia (slowness) rigidity (stiffness), and dyskinesias.  Individual ultrasound waves do not contain enough energy to do any damage as they pass […]

Read More

APDA funding is critical to new research in understanding Levodopa-induced dyskinesias

Posted on by Phil Franchina

In an exciting new study, researchers at the Graduate Center, City University of New York (CUNY) and the CUNY...see more School of Medicine, led by Dr. Andreas Kottmann, studied levodopa induced dyskinesias (LIDs) and demonstrated that inhibiting a protein called sonic hedgehog (Shh) decreased LIDs in animal models of PD. The study appears today in Communications […]

Read More

New Clinical Use for Gocovri

Posted on by Phil Franchina

Adamas announced that the Food and Drug Administration (FDA) approved Gocovri for a second indication – as an add-on...see more treatment to carbidopa/levodopa in Parkinson’s disease (PD) patients who are experiencing OFF episodes. Previously, Gocovri was only approved for treatment of Levodopa-induced dyskinesias. You can learn more about managing dyskinesias and OFF episodes in this webinar. […]

Read More

New technology from Abbott allows for remote programming of DBS device

Posted on by Phil Franchina

Abbott, one of the manufacturers of deep brain stimulation (DBS) devices for Parkinson’s disease (PD) recently released NeuroSphereTM Virtual...see more Clinic, a technology that allows for virtual visits between patients and their DBS neurologist and is the first system to allow for remote programming of the DBS device. Currently, a device can be programmed so that […]

Read More